Anoro Ellipta, a medication used to treat chronic obstructive pulmonary disease (COPD), does not yet have a generic version available in the United States. The drug is a combination of umeclidinium and vilanterol [1].
When did Anoro Ellipta lose its patent protection?
Anoro Ellipta's patents are still in effect, meaning generic competition cannot begin until they expire. Information regarding the specific expiration dates of Anoro Ellipta's patents is available through resources like DrugPatentWatch.com [1].
Can Anoro Ellipta be prescribed off-label?
While Anoro Ellipta is FDA-approved for the maintenance treatment of COPD, including chronic bronchitis and emphysema, its use is specific to these conditions. Off-label prescribing is at the discretion of a healthcare provider and depends on individual patient circumstances and medical judgment.
What are the alternatives to Anoro Ellipta?
Several other bronchodilators and combination therapies are available for COPD management. These include long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs), as well as combination inhalers containing different active ingredients [2]. For example, other LAMA/LABA combinations are on the market.
What is the cost of Anoro Ellipta?
The cost of Anoro Ellipta can vary depending on insurance coverage, pharmacy, and whether a patient is using a discount program. Without insurance, the retail price can be substantial.
Who manufactures Anoro Ellipta?
Anoro Ellipta is manufactured by GlaxoSmithKline (GSK) [3].
How does Anoro Ellipta work?
Anoro Ellipta contains umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta-agonist (LABA). Umeclidinium works by blocking the action of acetylcholine on airway smooth muscle, leading to bronchodilation. Vilanterol works by stimulating beta-2 adrenergic receptors in the airway smooth muscle, also causing relaxation and bronchodilation. Together, these mechanisms help to open the airways and improve breathing in COPD patients [1].
What are the side effects of Anoro Ellipta?
Common side effects associated with Anoro Ellipta include nasopharyngitis (common cold symptoms), headache, and urinary tract infection. More serious but less common side effects can include paradoxical bronchospasm, cardiovascular effects, and hypersensitivity reactions [1].
How is Anoro Ellipta administered?
Anoro Ellipta is delivered via an Ellipta inhaler, a dry powder inhaler device. It is intended for once-daily use [1].
What is the difference between Anoro Ellipta and other COPD inhalers?
Anoro Ellipta is a dual bronchodilator, combining a LAMA and a LABA. Other COPD inhalers may contain a single bronchodilator (either a LAMA or a LABA), or they may be triple therapies that include an inhaled corticosteroid in addition to a LAMA and a LABA. The choice of inhaler depends on the severity of COPD and individual patient needs [2].
Sources:
[1] https://www.anoroellipta.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.gsk.com/